logo
China to launch mission to capture pieces of an unusual asteroid

China to launch mission to capture pieces of an unusual asteroid

Boston Globe4 days ago

If Tianwen-2 pulls this off, China will become the third nation — after Japan and the United States — to retrieve pristine material from an asteroid.
'All Chinese planetary scientists are now finger-crossed for this historic mission,' said Yuqi Qian, a lunar geologist at the University of Hong Kong.
Advertisement
The spacecraft also has a secondary target, an unusual comet that it could study as part of an extended mission.
Visiting these objects will help reveal more about the building blocks of the worlds of the inner solar system. And as asteroids can pose an impact risk to Earth, missions to study the structures and mineral makeups of these objects can aid planning to deflect or vaporize them.
'A sample return mission is a gift that keeps on giving,' said Sara Russell, a planetary scientist at London's Natural History Museum.
Advertisement
While fragments of asteroids reach Earth's surface periodically, they are contaminated and altered when they plummet through the atmosphere. Scientists prefer untouched matter from the source, brought back to study in ultraclean laboratories.
'Sample return missions allow us to pick apart the physical and chemical properties of a body in a level of detail that's not possible with remote observations by telescopes and spacecraft,' said Ashley King, a meteoriticist also at the London museum.
China's space agency has executed two successful sample return missions to the moon — in 2020 and 2024. But Tianwen-2 (Tianwen is often translated as 'Questions to Heaven') is China's first foray into asteroid sample return.
Kamoʻoalewa, the asteroid it will visit, is somewhat peculiar. As a quasi-satellite earlier known as 2016 HO3, it loops around Earth, but it is not a true moon because it is gravitationally bound to the sun. Recent telescopic observations suggest it is made of the same volcanic matter found on the moon, implying that it is a piece of the lunar surface shorn off by a meteor impact.
'Kamoʻoalewa, therefore, potentially holds key information about the formation and evolution of the Earth-moon system,' King said.
However 'its origins remain an open question,' said Benjamin Sharkey, a planetary astronomer at the University of Maryland who made those recent telescopic observations. He said he was excited that Tianwen-2 was going to bring some of the asteroid home for study, which should close the case of Kamoʻoalewa's origins.
Kamoʻoalewa can get within 9 million miles of Earth, making it an easy target to reach. But diving down to sample it is risky. 'The sample collection and return are hardest,' Russell said, 'because humans have only a very limited amount of experience in doing both.'
Advertisement
The asteroid may be only 130 feet across — a small target. Its rapid rotation, about once every 28 minutes, poses additional challenges. 'You need to find ways to either grab the sample without landing or a way to hang on as it spins,' King said.
China's spacecraft may try doing both. 'Tianwen-2 will use two methods to collect samples from Kamoʻoalewa,' Qian said.
The first is 'Touch and Go,' a method employed by the US and Japanese asteroid missions: The spacecraft briefly makes contact with the object, kicks up the surface using compressed gas or a fired projectile, and captures jettisoned rocks before the spacecraft flees the scene.
The second method, 'Anchor and Attach,' has never been tested. Using a series of drills, Tianwen-2 will try to adhere to the asteroid before retrieving both shallow and deeper samples.
If Tianwen-2 navigates those dangers and eventually drops its bits of Kamoʻoalewa to Earth, it will then fly to the Comet 311P/PanSTARRS, arriving in the early 2030s to study it remotely.
Tianwen-2 is more than just a scientific sleuth. It is also a technological steppingstone for China's ambitious Tianwen-3 mission. Due to launch in 2028, it aims to retrieve rock samples from Mars and return them to Earth. A comparable effort led by the United States to achieve the same goal is facing major hurdles.
This article originally appeared in

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AstraZeneca, Daiichi announce results from three trials on DATROWAY
AstraZeneca, Daiichi announce results from three trials on DATROWAY

Business Insider

time4 hours ago

  • Business Insider

AstraZeneca, Daiichi announce results from three trials on DATROWAY

Results from three trials continue to demonstrate the potential of DATROWAY in combination with various immunotherapies to improve outcomes in patients with non-small cell lung cancer, NSCLC, across multiple stages of the disease. These results from TROPION-Lung02, TROPION-Lung04 and NeoCOAST-2 were presented at the 2025 American Society of Clinical Oncology Annual Meeting. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate, ADC, discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (AZN). In 42 patients receiving first-line doublet DATROWAY plus pembrolizumab, an objective response rate of 54.8% was observed. In 54 patients receiving first-line triplet DATROWAY plus pembrolizumab and platinum chemotherapy, an ORR of 55.6% was observed. This analysis included patients enrolled during the dose escalation phase of the trial, where 4.8% and 40.7% of patients treated with the doublet and triplet regimens, respectively, received DATROWAY at a dose of 4 mg/kg versus 6 mg/kg. First results from cohort 5 of the TROPION-Lung04 phase 1b trial, presented during a poster session on Saturday, May 31, showed DATROWAY plus AstraZeneca's PD-1/TIGIT bispecific antibody rilvegostomig as a first-line treatment demonstrated an ORR of 57.5%, including one complete response and 22 partial responses in 40 patients with advanced or metastatic NSCLC. A disease control rate of 95% was seen. Final results from Arm 4 of the NeoCOAST-2 phase 2 platform trial evaluating neoadjuvant DATROWAY plus AstraZeneca's anti-PD-L1 therapy IMFINZI and single-agent platinum chemotherapy were presented during a poster session on Saturday, May 31 and showed the combination demonstrated a pathologic complete response rate of 35.2%

Arvinas, Pfizer announce VERITAC-2 trial did not reach statistical significance
Arvinas, Pfizer announce VERITAC-2 trial did not reach statistical significance

Business Insider

time4 hours ago

  • Business Insider

Arvinas, Pfizer announce VERITAC-2 trial did not reach statistical significance

Arvinas (ARVN) and Pfizer (PFE) announced detailed results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer, MBC, whose disease progressed following prior treatment with cyclin-dependent kinase, CDK, 4/6 inhibitors and endocrine therapy. These data, which were highlighted in the American Society of Clinical Oncology press briefing and selected for Best of ASCO, will be presented today in a late-breaking oral presentation and have been simultaneously published in the New England Journal of Medicine. In the trial, vepdegestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, PFS, among patients with an estrogen receptor 1, ESR1, mutation, reducing the risk of disease progression or death by 43% compared to fulvestrant. The median PFS, as assessed by blinded independent central review, BICR, was 5.0 months with vepdegestrant versus 2.1 months with fulvestrant. Investigator-assessed PFS was consistent with the BICR-assessed PFS. In patients with ESR1 mutations, vepdegestrant demonstrated a consistent PFS benefit over fulvestrant across all pre-specified subgroups. The trial did not reach statistical significance in improvement in PFS in the intent-to-treat population, with a median PFS of 3.7 months for vepdegestrant versus 3.6 for fulvestrant.

China happy with restrictions on its students, lawmaker says
China happy with restrictions on its students, lawmaker says

Politico

time10 hours ago

  • Politico

China happy with restrictions on its students, lawmaker says

Rep. Raja Krishnamoorthi said Sunday the White House's move to revoke visas for Chinese students studying in the U.S. is likely to have the Chinese Communist Party 'cheering for this policy.' 'Because they want these people back,' Krishnamoorthi (D-Ill.) told CBS' Margaret Brennan on Sunday on 'Face the Nation.' 'They want the scientists and the entrepreneurs and the engineers who can come and help their economy. And so we are probably helping them, as well as other countries, more than helping ourselves with this policy.' Secretary of State Marco Rubio last Wednesday announced the measure to aggressively revoke 'visas of Chinese students, including those with connections to the Chinese Communist Party or studying in critical fields.' Roughly 277,000 Chinese students studied in the U.S. last year. And nearly 20 percent of Silicon Valley's highly educated tech employees come from China. But the details behind the White House push — including whether the administration plans to target every Chinese international student — remain unclear. Tensions between the two countries, already roiled by high-stakes tariff negotiations, have further strained. 'There's not enough details,' Krishmanoorthi, who launched a run for Illinois' open U.S. Senate seat in May, told Brennan. 'However, this appears to be much broader and it's terribly misguided and it appears prejudicial and discriminatory.' Krishnamoorthi is the ranking member on the House Select Committee on the Strategic Competition Between the U.S. and the Chinese Communist Party. He told Brennan that increased scrutiny on Chinese students can make sense. 'I think that you should definitely have heightened vetting, especially in certain critical areas because we know that the CCP tries to steal, for instance, intellectual property or worse,' Krishnamoorthi said. 'But the way that this is currently structured looks very, very suspicious.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store